CN106456552A - S1p调节剂的立即释放剂量方案 - Google Patents

S1p调节剂的立即释放剂量方案 Download PDF

Info

Publication number
CN106456552A
CN106456552A CN201580031360.0A CN201580031360A CN106456552A CN 106456552 A CN106456552 A CN 106456552A CN 201580031360 A CN201580031360 A CN 201580031360A CN 106456552 A CN106456552 A CN 106456552A
Authority
CN
China
Prior art keywords
day
xin bomode
patient
dosage form
xin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580031360.0A
Other languages
English (en)
Chinese (zh)
Inventor
E·勒冈诺克斯
E·瓦尔斯特伦
P·M·R·博伊洛特
E·雷纳德
F·达尔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106456552(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN202310667400.7A priority Critical patent/CN116650467A/zh
Publication of CN106456552A publication Critical patent/CN106456552A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580031360.0A 2014-04-10 2015-04-08 S1p调节剂的立即释放剂量方案 Pending CN106456552A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310667400.7A CN116650467A (zh) 2014-04-10 2015-04-08 S1p调节剂的立即释放剂量方案

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
US61/977,816 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310667400.7A Division CN116650467A (zh) 2014-04-10 2015-04-08 S1p调节剂的立即释放剂量方案

Publications (1)

Publication Number Publication Date
CN106456552A true CN106456552A (zh) 2017-02-22

Family

ID=52988364

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580031360.0A Pending CN106456552A (zh) 2014-04-10 2015-04-08 S1p调节剂的立即释放剂量方案
CN202310667400.7A Pending CN116650467A (zh) 2014-04-10 2015-04-08 S1p调节剂的立即释放剂量方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310667400.7A Pending CN116650467A (zh) 2014-04-10 2015-04-08 S1p调节剂的立即释放剂量方案

Country Status (16)

Country Link
US (4) US20170027907A1 (enExample)
EP (3) EP4074312B1 (enExample)
JP (1) JP6674903B2 (enExample)
KR (2) KR20160141841A (enExample)
CN (2) CN106456552A (enExample)
AU (2) AU2015246036A1 (enExample)
CA (1) CA2943598C (enExample)
CL (1) CL2016002562A1 (enExample)
IL (2) IL305337A (enExample)
MX (1) MX2016013245A (enExample)
PH (1) PH12016501965A1 (enExample)
RU (2) RU2020107732A (enExample)
SG (1) SG11201607894RA (enExample)
TW (1) TW201622721A (enExample)
WO (1) WO2015155709A1 (enExample)
ZA (1) ZA201606519B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
CN111107845A (zh) * 2017-09-29 2020-05-05 诺华股份有限公司 西尼莫德的给药方案
CN111132677A (zh) * 2017-09-29 2020-05-08 诺华股份有限公司 西尼莫德的给药方案

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
EP4074312B1 (en) * 2014-04-10 2026-02-25 Novartis AG Siponimod immediate release dosage regimen for treating autoimmune diseases
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
SI3758708T1 (sl) 2018-03-01 2025-04-30 Astrazeneca Ab Farmacevtski sestavki, ki vsebujejo (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil}-1,4-oksazepan-2-karboksamid
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264363A (zh) * 2008-12-22 2011-11-30 诺瓦提斯公司 S1p受体激动剂的给药方案
WO2012095853A1 (en) * 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
CN103458877A (zh) * 2011-01-07 2013-12-18 诺华股份有限公司 免疫抑制性制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160064245A (ko) * 2008-12-18 2016-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
AR074826A1 (es) * 2008-12-22 2011-02-16 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p
AU2010300919A1 (en) * 2009-09-29 2012-03-22 Novartis Ag Dosage regimen of an S1P receptor modulator
BR112014009141A8 (pt) * 2011-10-21 2017-06-20 Novartis Ag regime de dosagem para um modulador ou agonista do receptor s1p
EP4074312B1 (en) * 2014-04-10 2026-02-25 Novartis AG Siponimod immediate release dosage regimen for treating autoimmune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264363A (zh) * 2008-12-22 2011-11-30 诺瓦提斯公司 S1p受体激动剂的给药方案
CN103458877A (zh) * 2011-01-07 2013-12-18 诺华股份有限公司 免疫抑制性制剂
WO2012095853A1 (en) * 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111107845A (zh) * 2017-09-29 2020-05-05 诺华股份有限公司 西尼莫德的给药方案
CN111132677A (zh) * 2017-09-29 2020-05-08 诺华股份有限公司 西尼莫德的给药方案
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法

Also Published As

Publication number Publication date
US20250041266A1 (en) 2025-02-06
AU2015246036A1 (en) 2016-10-13
EP4074312B1 (en) 2026-02-25
MX2016013245A (es) 2017-01-16
JP6674903B2 (ja) 2020-04-01
CA2943598C (en) 2023-03-07
AU2020203107A1 (en) 2020-05-28
RU2715734C2 (ru) 2020-03-03
KR20160141841A (ko) 2016-12-09
EP4074312A1 (en) 2022-10-19
EP3129020A1 (en) 2017-02-15
RU2020107732A (ru) 2020-03-30
IL247986A0 (en) 2016-11-30
US20220016076A1 (en) 2022-01-20
CL2016002562A1 (es) 2017-07-28
CN116650467A (zh) 2023-08-29
AU2020203107B2 (en) 2021-10-21
JP2017510607A (ja) 2017-04-13
US20170027907A1 (en) 2017-02-02
EP3831378A1 (en) 2021-06-09
KR20220156981A (ko) 2022-11-28
WO2015155709A1 (en) 2015-10-15
SG11201607894RA (en) 2016-10-28
IL305337A (en) 2023-10-01
US20190054065A1 (en) 2019-02-21
RU2016143979A (ru) 2018-05-14
TW201622721A (zh) 2016-07-01
RU2016143979A3 (enExample) 2018-11-12
ZA201606519B (en) 2017-11-29
CA2943598A1 (en) 2015-10-15
PH12016501965A1 (en) 2017-01-09

Similar Documents

Publication Publication Date Title
AU2020203107B2 (en) S1P modulator immediate release dosage regimen
TWI632909B (zh) 治療阿滋海默症之方法以及其醫藥組成物
US11654113B2 (en) Modified release formulations and uses thereof
US12533340B2 (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US20210177783A1 (en) Compositions and methods for treating alzheimer's disease and parkinson's disease
NL8600161A (nl) Farmaceutische preparaten die 9,10-dihydroergotalkaloiden bevatten.
US11179377B2 (en) Pharmaceutical compositions and uses thereof
CA3105680A1 (en) Treatment of the pruritic symptoms of liver disease
HK40053433A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
HK40081576A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
CA2973540C (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
TW202527911A (zh) 用於治療猝睡症的化合物
IL323027A (en) Formulation
TW202237084A (zh) 修飾釋放調配物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170222